Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Total Valuation
TG Therapeutics has a market cap or net worth of $5.53B. The enterprise value is $5.85B.
Market Cap$5.53B
Enterprise Value$5.85B
Share Statistics
TG Therapeutics has 158,665,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding158,665,620
Owned by Insiders9.80%
Owned by Institutions0.07%
Financial Efficiency
TG Therapeutics’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 7.84%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)7.84%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee934.67K
Profits Per Employee66.43K
Employee Count352
Asset Turnover0.57
Inventory Turnover0.35
Valuation Ratios
The current PE Ratio of TG Therapeutics is 93.2. TG Therapeutics’s PEG ratio is 2.36.
PE Ratio93.2
PS Ratio13.29
PB Ratio19.67
Price to Fair Value19.67
Price to FCF-107.84
Price to Operating Cash Flow-91.10
PEG Ratio2.36
Income Statement
In the last 12 months, TG Therapeutics had revenue of 329.00M and earned 23.38M in profits. Earnings per share was 0.16.
Revenue329.00M
Gross Profit290.52M
Operating Income41.93M
Pretax Income25.59M
Net Income23.38M
EBITDA49.90M
Earnings Per Share (EPS)0.16
Cash Flow
In the last 12 months, operating cash flow was -59.13M and capital expenditures -112.00K, giving a free cash flow of -59.24M billion.
Operating Cash Flow-59.13M
Free Cash Flow-59.24M
Free Cash Flow per Share-0.37
Dividends & Yields
TG Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.26
52-Week Price Change48.73%
50-Day Moving Average32.13
200-Day Moving Average34.63
Relative Strength Index (RSI)51.90
Average Volume (3m)1.86M
Important Dates
TG Therapeutics upcoming earnings date is Oct 30, 2025, TBA (Confirmed).
Last Earnings DateAug 4, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
TG Therapeutics as a current ratio of 6.25, with Debt / Equity ratio of 91.78%
Current Ratio6.25
Quick Ratio5.03
Debt to Market Cap0.06
Net Debt to EBITDA1.49
Interest Coverage Ratio1.75
Taxes
In the past 12 months, TG Therapeutics has paid 2.21M in taxes.
Income Tax2.21M
Effective Tax Rate0.09
Enterprise Valuation
TG Therapeutics EV to EBITDA ratio is 89.15, with an EV/FCF ratio of -109.67.
EV to Sales13.52
EV to EBITDA89.15
EV to Free Cash Flow-109.67
EV to Operating Cash Flow-109.79
Balance Sheet
TG Therapeutics has $251.87M in cash and marketable securities with $253.72M in debt, giving a net cash position of -$1.85M billion.
Cash & Marketable Securities$251.87M
Total Debt$253.72M
Net Cash-$1.85M
Net Cash Per Share-$0.01
Tangible Book Value Per Share$1.53
Margins
Gross margin is 86.96%, with operating margin of 12.74%, and net profit margin of 7.11%.
Gross Margin86.96%
Operating Margin12.74%
Pretax Margin7.78%
Net Profit Margin7.11%
EBITDA Margin15.17%
EBIT Margin15.08%
Analyst Forecast
The average price target for TG Therapeutics is $44.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$44.00
Price Target Upside26.91% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast30.96%
EPS Growth Forecast-38.30%